Symbicort SMART (Symbicort Maintenance And Reliever Therapy)

AstraZeneca2,000 enrolled

Overview

The purpose of this study is to investigate the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy.

Study Type

OBSERVATIONAL

Enrollment

2,000

Conditions

Asthma

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this program. Exclusion Criteria: * Since this programme intends to describe Symbicort use in routine clinical practice when prescribed as Symbicort maintenance and reliever therapy, there are no programme specific exclusion criteria, other than: involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)

Locations (3)

Research Site

Seoul, Jongro-gu, South Korea

Research Site

Seoul, Kangnam-gu, South Korea

Research Site

Seoul, Songpa-gu, South Korea

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.